A Study to investigate AZD2796, a LILRB2 inhibitor, in Adult Patients with Advanced Solid Tumors
Research type
Research Study
Full title
A Phase I/IIa, Open-label, Modular, Dose Escalation, and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2796, an Anti-LILRB2 Antibody, as monotherapy (or in combination) in Adult Patients with Advanced Solid Tumors.
IRAS ID
1009199
Contact name
Venkat Chintapalli
Contact email
Sponsor organisation
AstraZeneca AB
Research summary
The purpose of this study to learn more about a medication called AZD2796, to study if AZD2796 will be safe and effective for the treatment of different cancers when it is given by itself or when it is given with other medication, and also to better understand specific types of cancer and associated health problems.
AZD2796 is an investigational drug that is a type of anti-cancer treatment called immunotherapy. Immunotherapy helps the white blood cells in your body (immune system) to fight and destroy cancer cells. AZD2796 is considered investigational because it is not approved by any health authority, except for use in research studies like this.
The study will be conducted in separate parts called modules. Participants are being invited to participate in Module 1 of the study. About 46 participants will take part in Module 1. Module 1 will consist of a dose escalation cohort and a pharmacodynamic (PD) cohort. The aim of the dose escalation cohort is to determine the safety, tolerability, pharmacokinetics (PK) (what your body does to the study drug) and/or preliminary anti-tumour activity of the study drug in participants with advanced solid tumours. The PD cohort is designed to find out more about the drug, how it works in the body, and what the drug does to the body. Participants included in the PD cohort will be asked to undergo a tissue biopsy at Visit 1 and Visit 7 to see what effects the treatment is having on their cancer.
AZD2796 will be administered by intravenous infusion (a method of delivering the study drug directly into a person’s blood stream through a small tube called a catheter) once every 3 weeks.The Sponsor of the study is AstraZeneca AB.
REC name
South Central - Oxford C Research Ethics Committee
REC reference
24/SC/0032
Date of REC Opinion
13 Mar 2024
REC opinion
Further Information Favourable Opinion